Key partners and channels are academic institutions (research and IP), health institutions and health care professionals (consultancy, pre-clinical and clinical research, and sales), manufacturers (contract manufacturing and mass production), reimbursement consultants and Health Insurance Funds (private and public reimbursement), media and marketing agencies (promotion and publicity), distributors and wholesalers (sales and distribution), patient advocacy groups and customers (advocacy and sales).
Product development, safety, trainings, QA, pre-clinical and clinical trials, regulatory and certification, data analytics, business consultancy, marketing authorization, reimbursement and pricing, legal, IP protection, production, marketing and sales, customer relationship management, company development
Tangible (financials, facilities, raw materials, packaging, fixed assets etc.)
Intangible (social capital, technological knowledge, know-how, networks etc.)
Human (highly specialized experts, highly effective teams, strong corporate culture etc.)
Urinary catheterization without infection and with less complications, and better quality of life due to usage with less discomfort
EM-CATH value proposal is very simple – resolving medical issues and improving quality of life. EM-CATH provides urinary catheterization without infection, with less complications, discomfort, pain and suffering, lowered stress, social anxiety and inconvenience, resulting in restoring overall functionality in daily activities and lowering catheterization-related costs. EM-CATH will provide high value added to the customers
Development of demand, i.e. pre-marketing activities, starting with introduction and consultation with key opinion leaders, decision makers, financiers, administrators of the device, and end users (urologists, nurses, hospitals, HIFs, patients etc.), followed by endorsement through compassionate use of EM-CATH upon pre-clinical trials by eminent world-class urologists and medical device experts.
Upon granting Marketing Authorization post-marketing activities include promotion and sales value-centric legally accepted actions such as intensive personal selling, PR and publicity, sponsorships, sales promotion, branding, continuing education and word-of-mouth (advertising is strictly forbidden), through selected available offline and online media (publications, presentations, promo materials, websites, databases, social media, search engines, mail, TV, radio, conferences, exhibitions and fairs, sales representatives, advocacy groups, etc.).
Distributors and wholesalers, National Health Insurance funds (HIFs), reimbursement companies, online platforms, direct sales, patient advocacy groups
EM-CATH will operate predominantly on B2B market, including:
Healthcare institutions, both public and private, on primary, secondary, tertiary & quaternary level, including general care, hospitals, clinics, health centers, etc.
Home and community care subjects, both public and private, including elderly care, self-care, home care, long-term care, assisted living, rehabilitation centers, etc.
Entrance on the B2C market is planned at later stages.
The waste majority of costs (over 80%) will include product development costs, regulatory costs, manufacturing costs and marketing and sales. Other costs include transport, logistics, indirect and overhead costs (about 20%)
Revenues from healthcare institutions, both public and private, on primary, secondary, tertiary & quaternary level, including general care, hospitals, clinics, health centers, etc.
Revenues from home and community care subjects, both public and private, including elderly care, self-care, home care, long-term care, assisted living, rehabilitation centers, etc.
Revenues from B2C sales – pharmacies, point-of-care etc.